Related Experiment Video
Updated: Mar 6, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
Gavin G Meredith1, Paul A Schkade2, Brian C Joondeph1,3
1Rocky Vista University College of Osteopathic Medicine, Parker, Colorado.
Purpose:
To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.
Methods:
Clinical case report.
Results:
Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.
Conclusion:
Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
More Related Videos
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
Allergic Drug Reactions
Allergic Reactions: Anaphylaxis
Allergic Reactions
Drug Toxicity: Allergic Reactions